We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

198 hedge funds and large institutions have $1.46B invested in Myriad Genetics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 72 increasing their positions, 65 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more call options, than puts

Call options by funds: $4.2M | Put options by funds: $755K

11% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 65

0.87% more ownership

Funds ownership: 98.56% → 99.43% (+0.87%)

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

3% less funds holding

Funds holding: 205 → 198 (-7)

27% less capital invested

Capital invested by funds: $1.99B → $1.46B (-$532M)

Holders
198
Holders Change
-7
Holders Change %
-3.41%
% of All Funds
3.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
72
Reduced
65
Closed
24
Calls
$4.2M
Puts
$755K
Net Calls
+$3.45M
Net Calls Change
-$2.92M

Top Buyers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
+$31.1M
2
PAMP
Polar Asset Management Partners
Ontario, Canada
+$22.1M
3
State Street
State Street
Massachusetts
+$12.6M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.02M
5
SEI Investments
SEI Investments
Pennsylvania
+$6.03M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$14.6M
2
JP Morgan Chase
JP Morgan Chase
New York
-$10.2M
3
Millennium Management
Millennium Management
New York
-$7.16M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.94M
5
Man Group
Man Group
United Kingdom
-$5.65M

MYGN Hedge Fund Activity: Q2 2022 in Review

198 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2022, worth a combined $1.46B — down 27% from $1.99B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of MYGN and 22 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 72 added.

The largest buyer was Camber Capital Management, adding an estimated $31.1M. The largest seller was PFM Health Sciences, cutting an estimated $14.6M.

  • 198 institutional investors held Myriad Genetics (MYGN) as of Q2 2022, down from 205 in Q1 2022.
  • Funds reported $1.46B of Myriad Genetics stock for Q2 2022, down 27% quarter-over-quarter.
  • 22 funds opened new Myriad Genetics positions in Q2 2022 and 24 closed out, a net change of -2 holders.
  • The largest Myriad Genetics buyer in Q2 2022 was Camber Capital Management, an estimated $31.1M added.
  • The largest Myriad Genetics seller in Q2 2022 was PFM Health Sciences, an estimated $14.6M sold.

Based on aggregated 13F filings for Q2 2022.